US/SWITZERLAND: ZELLER COOPERATES WITH SKB

Article Abstract:

Switzerland's leading producer of phytopharmaceuticals, Max Zeller Sohne AG of Romanshorn, has gained a foothold on the US market by signing a cooperation agreement with SmithKline Beecham. The US company will market Zeller's Alluna sleeping pill in the US. In 1999 sleeping pills contributed almost 50% to Zeller's turnover, which grew 13% to SFr 22.3mn. Sales on the home market increased 10%. For year 2000 Zeller expects a sales growth of 30%. It sees great potential on the US market for phytopharmaceuticals, which is worth about US$ 2bn. The Swiss company has seen its sales grow also in Latin America, while sales in Germany declined as a result of the health care reform. The Swiss market for phytopharmaceuticals has been stagnating for the past ten years. In 1999 sales of natural medicines at consumer prices amounted to SFr 282mn, up 1% from 1998. Phytopharmaceuticals accounted for SFr 228mn (up 0.5%) of the total. Together with Novartis' Valverde products, Zeller claims a market share of 13%. Zeller spends 15% of turnover on research and development annually.

Strategy & planning, Sales & consumption, Vitamin, Nutrient & Hematinic Preps, SmithKline Beecham Corp. (Philadelphia, Pennsylvania), Max Zeller Sohne AG

---

US/SWITZERLAND: EMISPHERE LICENCE TO NOVARTIS

Article Abstract:

Emisphere Technologies Inc. of Tarrytown, New Jersey has granted Novartis an exclusive licence for the development and marketing of oral calcitonin. Currently the product that is effective against osteoporosis is only available as injections.

Strategic alliances, Muscle System Preparations, Emisphere Technologies Inc., EMIS

---

US/SWITZERLAND: NOVARTIS, RIGEL R&D DEAL

Article Abstract:

Rigel Inc., a biotechnology company based in South San Francisco, has been commissioned by Novartis to identify drug targets in the field of respiratory diseases for the Swiss pharmaceutical maker.

Research & development outlays, Respiratory Preparations, Respiratory system agents, Rigel Inc.

Similar abstracts:

• Abstracts: SWITZERLAND/UK: ROCHE/VERNALIS DEVELOPING TOGETHER. SWITZERLAND/US: CANCER R&D DEAL BY ROCHE, BMS. SWITZERLAND/UK: LONZA, CELLTECH COOPERATE
• Abstracts: SWITZERLAND/US: ROCHE TO USE CHIRON TECHNOLOGY. NETHERLANDS: ORGANON ACQUIRES DELTA DRUG. NETHERLANDS/SWITZERLAND: ORGANON/ROCHE DEAL
• Abstracts: GERMANY: NEW COATING TECHNOLOGY BY BASF. GERMANY: ACRYLIC DISPERSION INVESTMENT BY BASF. GERMANY: HERBERTS DIVESTS FURNITURE COATINGS

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.